Re: Indian Drug Maker to Produce Generic Version of Tamiflu

[Guest guest]

Wonderful! This should spur Roche to license generic versions of

Tamiflu.

[Guest guest]

Roche will probably be one huge pain in the ass about this. Lee <jackalope_lepus@...> wrote:

Wonderful! This should spur Roche to license generic versions of Tamiflu.

Never place a period where God has placed a comma. - Gracie

[Guest guest]

>

> Wonderful! This should spur Roche to license generic versions of

> Tamiflu.

>

I got that news from Health itself, burried in today's news.

[Guest guest]

Wonderful! This should spur Roche

to license generic versions of

> Tamiflu.

>

>

>

>

>

>

[Guest guest]

Bush should show up at a Roche shareholders meeting to talk about

patriotism and sacrifice. Why should the kids who join the military be

the only ones to hear that lecture?

>

> Roche will probably be one huge pain in the ass about this.

[Guest guest]

Dream on, friend. It'll never happen.Lee <jackalope_lepus@...> wrote:

Bush should show up at a Roche shareholders meeting to talk about patriotism and sacrifice. Why should the kids who join the military be the only ones to hear that lecture?>> Roche will probably be one huge pain in the ass about this.

Never place a period where God has placed a comma. - Gracie

[Guest guest]

>

> Dream on, friend. It'll never happen.

This might be a repeat here, but pay attention to the last paragraph.

October 08, 2005 03:51 AM ET

Bird flu fight lifts biotech stocks

[Reuters]

NEW YORK (Reuters) - Shares of biotechnology companies developing

treatments to fight a possible outbreak of avian flu rose on Friday as

delegates from around the world met to discuss plans for battling the

illness.

BioCryst Pharmaceuticals Inc. , a small biotech in Birmingham,

Alabama, saw its shares soar as much as 20 percent to its highest

price in nearly five years, while Gilead Sciences Inc. shares rose 5

percent to touch an all-time high.

" The current marketers of (antiviral drugs) Relenza and Tamiflu have

been doing well, " said Wedbush Securities analyst Vinny Jindal.

" And really, any company with a capability for making viral vaccines

has had some appreciation. "

Shares of Gilead, which co-developed Tamiflu with Swiss drug maker

Roche Holding AG , provided the greatest support to the Nasdaq in

afternoon trading.

Delegates from 80 countries and international agencies began a meeting

in Washington on Thursday to formulate the best way to fight the

growing outbreak of avian influenza.

BioCryst is developing a drug which, if approved, could be a third

option to treat the H5N1 avian influenza, which has already killed

more than 100 people in Asia and could turn into a pandemic that could

kill millions if it mutates into a more deadly version of the virus,

experts have said.

Jindal said the overall market for avian flu drugs could easily reach

$10 billion.

" With two drugs approved and peramivir being the lead drug on the

horizon, it's an opportunity for hundreds of millions for BioCryst, "

he said.

Jindal said Tamiflu had sales of $450 million during the first half of

this year, even before many national and international orders.

Since GlaxoKline , which makes Relenza, and Roche are limited as

to how much they can produce, Jindal said countries might buy

peramivir just to have something.

BioCryst's drug peramivir is an antiviral drug that can be directly

injected into the bloodstream, meaning it could probably work faster

than Tamiflu, which is a pill, and Relenza, which is inhalable.

The company plans to begin testing it in humans in January. Because

peramivir targets a public health threat it can be stockpiled without

undergoing the same lengthy testing process required by U.S.

regulators to get to market.

The company will not begin mass-production until it gets stockpiling

orders, but BioCryst Chief Executive Bugg told Reuters the

company had enough in hand to treat 15,000 to 20,000 people, and has

already placed orders for raw materials to make enough to treat up to

another million.

" I can't even come close to quantitating what the financial return is

to BioCryst, but I do feel that we have a chance to make a major

difference, " he said. Aside from avian flu, peramivir could be used to

treat patients who are very ill with severe influenza, he said.

BioCryst's stock has nearly tripled since June, far outperforming the

16 percent gain seen by its larger cap peers on the American Stock

Exchange Biotech Index.

" What's driving this is that the market and the public are finally

noticing that BioCryst has one of the only active agents against

influenza and avian flu, " Jindal said.

Gilead, whose shares have gained 44 percent since February, is seeking

to end its Tamiflu pact with Roche as it claims the Swiss drugmaker

failed to adequately promote the drug.

Separately on Friday, President W. Bush met with chief

executives of drug companies to urge them to get into the

vaccine-making business, which is historically less lucrative than

making medicines. Glaxo is working on a vaccine for H5N1, as are

Chiron Corp. and France's Sanofi-Aventis

..

On Friday, shares of Gilead closed up $1.99 at $47.51, off a high of

$47.83, while BioCryst finished up $1.39 at $11.65 from its high of

$12.36 on the Nasdaq.

[Guest guest]

GWB can urge all he wants. That doesn't amount to a hill of beans, of course, since the companies can do what they please.cginca96 <cginca96@...> wrote:

>> Dream on, friend. It'll never happen.This might be a repeat here, but pay attention to the last paragraph.October 08, 2005 03:51 AM ETBird flu fight lifts biotech stocks[Reuters]NEW YORK (Reuters) - Shares of biotechnology companies developingtreatments to fight a possible outbreak of avian flu rose on Friday asdelegates from around the world met to discuss plans for battling theillness.BioCryst Pharmaceuticals Inc. , a small biotech in Birmingham,Alabama, saw its shares soar as much as 20 percent to its highestprice in nearly five years, while Gilead Sciences Inc. shares rose 5percent to touch an all-time high."The current marketers of (antiviral drugs) Relenza and Tamiflu havebeen doing well," said Wedbush

Securities analyst Vinny Jindal."And really, any company with a capability for making viral vaccineshas had some appreciation."Shares of Gilead, which co-developed Tamiflu with Swiss drug makerRoche Holding AG , provided the greatest support to the Nasdaq inafternoon trading.Delegates from 80 countries and international agencies began a meetingin Washington on Thursday to formulate the best way to fight thegrowing outbreak of avian influenza.BioCryst is developing a drug which, if approved, could be a thirdoption to treat the H5N1 avian influenza, which has already killedmore than 100 people in Asia and could turn into a pandemic that couldkill millions if it mutates into a more deadly version of the virus,experts have said.Jindal said the overall market for avian flu drugs could easily reach$10 billion."With two drugs approved and peramivir being the lead drug on thehorizon, it's an

opportunity for hundreds of millions for BioCryst,"he said.Jindal said Tamiflu had sales of $450 million during the first half ofthis year, even before many national and international orders.Since GlaxoKline , which makes Relenza, and Roche are limited asto how much they can produce, Jindal said countries might buyperamivir just to have something.BioCryst's drug peramivir is an antiviral drug that can be directlyinjected into the bloodstream, meaning it could probably work fasterthan Tamiflu, which is a pill, and Relenza, which is inhalable.The company plans to begin testing it in humans in January. Becauseperamivir targets a public health threat it can be stockpiled withoutundergoing the same lengthy testing process required by U.S.regulators to get to market.The company will not begin mass-production until it gets stockpilingorders, but BioCryst Chief Executive Bugg told Reuters

thecompany had enough in hand to treat 15,000 to 20,000 people, and hasalready placed orders for raw materials to make enough to treat up toanother million."I can't even come close to quantitating what the financial return isto BioCryst, but I do feel that we have a chance to make a majordifference," he said. Aside from avian flu, peramivir could be used totreat patients who are very ill with severe influenza, he said.BioCryst's stock has nearly tripled since June, far outperforming the16 percent gain seen by its larger cap peers on the American StockExchange Biotech Index."What's driving this is that the market and the public are finallynoticing that BioCryst has one of the only active agents againstinfluenza and avian flu," Jindal said.Gilead, whose shares have gained 44 percent since February, is seekingto end its Tamiflu pact with Roche as it claims the Swiss drugmakerfailed to adequately promote the

drug.Separately on Friday, President W. Bush met with chiefexecutives of drug companies to urge them to get into thevaccine-making business, which is historically less lucrative thanmaking medicines. Glaxo is working on a vaccine for H5N1, as areChiron Corp. and France's Sanofi-Aventis.On Friday, shares of Gilead closed up $1.99 at $47.51, off a high of$47.83, while BioCryst finished up $1.39 at $11.65 from its high of$12.36 on the Nasdaq.

Never place a period where God has placed a comma. - Gracie

[Guest guest]

From the article: The company plans to begin testing it in

humans in January. Because

peramivir targets a public health threat it can be

stockpiled without undergoing the same lengthy testing process required by U.S.

regulators to get to market.

Why not just use curcumin?! Same “testing” goin’

on. LOL!